Works matching IS 01435221 AND DT 2018 AND VI 132 AND IP 10

Results: 5
    1

    PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.

    Published in:
    Clinical Science, 2018, v. 132, n. 10, p. 1075, doi. 10.1042/CS20180040
    By:
    • Croyal, Mikaël;
    • Thi-Thu-Trang Tran;
    • Blanchard, Rose Hélène;
    • Le Bail, Jean-Christophe;
    • Villard, Elise F.;
    • Poirier, Bruno;
    • Aguesse, Audrey;
    • Billon-Crossouard, Stéphanie;
    • Ramin-Mangata, Stéphane;
    • Blanchard, Valentin;
    • Nativel, Brice;
    • Chemello, Kévin;
    • Khantalin, Ilya;
    • Thedrez, Aurélie;
    • Janiak, Philip;
    • Krempf, Michel;
    • Boixel, Christophe;
    • Lambert, Gilles;
    • Guillot, Etienne
    Publication type:
    Article
    2
    3
    4
    5